Capacity development, training and research uptake

PO - (8515) - CAPACITY BUILDING IN PREPARATION FOR HIV VACCINE TRIAL: GLOBALLY RELEVANT AIDS VACCINE EUROPE-AFRICA TRIALS PARTNERSHIP (GREAT)

Kilembe, William (Zambia); Okech, Brenda (Uganda); Nielsen, Leslie (Uganda); Muturi-Kioi, Vincent (Kenya); Jaoko, Walter (Kenya); Mutua, Gaudensia (Kenya); Sanders, Eduard (Kenya); Mpendo, Juliet (Uganda); Gumbe, Anne (Kenya); Chinyenzi, Kundai (Kenya); De Bont, Jan (Uganda); Kuipers, Hester (Netherlands); Crook, Alison (United Kingdom); King, Deborah (United Kingdom); Kaleebu, Pontiano (Uganda); Fast, Patricia (United States of America); Hanke, Tomas (United Kingdom)

1 - Zambia Emory HIV Research Project; 2 - Uganda Virus Research Institute - International AIDS Vaccine Initiative; 3 - International AIDS Vaccine Initiative; 4 - University of Nairobi; 5 - Kenya Medical Research Institute; 6 - International AIDS Vaccine Initiative - Human Immunology Laboratory; 7 - Medical Research Council - Uganda Virus Research Institute; 8 - University of Oxford

Background: The Globally Relevant AIDS Vaccine Europe-Africa Trials (GREAT) partnership is an EDCTP funded project that aims to foster collaboration between European and sub-Saharan African (SSA) institutions to build capacity among African clinical research centers (CRCs) in the design and conduct of HIV-1 vaccine efficacy trials.

Methods: In January 2017, The University of Oxford (UOXF) and five CRCs in Kenya, Uganda and Zambia were awarded a 5-year grant for capacity building and to support conduct of an HIV-1 vaccine trial in different high-risk populations across Africa using cross-clade (conserved protein regions) T-cell vaccines. UOXF and CRCs embarked on activities to strengthen capacity of the CRC for future efficacy trials. This included training, community engagement, cohort preparedness and infrastructure upgrade.

Results: In year 1, the African investigators at the CRCs collaborated on the development of a protocol aimed at assessing the safety and immunogenicity of the tHIVconsvX vaccines. In preparation for the planned vaccine trial, infrastructure upgrades were prioritized at all partner sites and this included building laboratory space and procurement of appropriate laboratory equipment. Planned infrastructure upgrades will also ensure that high risk populations can be safely and confidentially included in HIV prevention clinical trials. Systematic community engagement was implemented at all sites, training in GCP/GCLP was provided and training is planned for nominated CRC staff to lead community engagement efforts.

Conclusions: Improved infrastructure and the provision of targeted training will enhance future trials and increase the capacities of CRCs and staff to conduct quality trials in previously difficult-to-reach populations. Early collaboration between investigators from European and SSA institutions, with equal responsibilities in the protocol development process, makes meaningful partnership. EDCTP funding also offers a unique opportunity for capacity building.